Available Clinical Trials

Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Double-Blind Study of Adjuvant Cemiplimab Vs Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

A multicenter, randomized, double-blinded, placebo-controlled, Phase 3 trial of adjuvant Avelumab in Merkel cell carcinoma patients with lymph node metastases

A Phase 1 Study Of Pre-Operative Cemiplimab For Patients With Recurrent Cutaneous Squamous Cell Carcinoma

SPIND - Fecal microbiota transplant for immunotherapy-resistant metastatic Merkel cell carcinoma

Hypofractionated Radiation Therapy for Merkel Cell Carcinoma

Anatomically Directed Therapy for Merkel Cell Carcinoma in the Modern Era

Histologic, Molecular, and Genetic Prognostic Factors in Merkel Cell Carcinoma

A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab vs placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma

Adjuvant Avelumab in Merkel Cell Cancer (ADAM)

Pembrolizumab Vs Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma

Study of Adjuvant Cemiplimab Vs Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma